INKTHIGH SIGNALFINANCIAL10-K

INKT achieved a dramatic 192% increase in cash position to $13.4M while improving operating cash flow burn by 38%, signaling successful capital raising despite continued losses.

The substantial cash infusion provides critical runway for this biotech company's operations and R&D activities, while the improved cash burn rate suggests better operational efficiency. However, net losses increased to $12.5M and stockholders' equity remains deeply negative at -$14.2M, indicating ongoing dilution concerns and fundamental profitability challenges that investors must monitor closely.

Comparing 2026-03-31 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

INKT experienced a transformative financial period with cash and equivalents nearly tripling to $13.4M and total assets growing 149%, clearly indicating successful fundraising activity. While the company improved its operating cash flow burn by 38% to -$5.9M and reduced capital expenditures by 71%, net losses still increased 16% to $12.5M. The overall picture shows a biotech company that has secured near-term funding survival but continues to face significant cash burn and profitability challenges, with current liabilities of $13.0M nearly matching the cash position.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+191.9%
$4.6M→$13.4M

Cash position surged 191.9% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+177.6%
$5.0M→$13.8M

Current assets grew 177.6% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+148.9%
$5.7M→$14.2M

Asset base grew 148.9% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+87.2%
$7.0M→$13.0M

Current liabilities surged 87.2% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-70.6%
$250K→$74K

Capex reduced 70.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+38%
-$9.6M→-$5.9M

Operating cash flow surged 38% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+27.4%
-$19.6M→-$14.2M

Equity base grew 27.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
-15.9%
-$10.8M→-$12.5M

Net income declined 15.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-12%
-$11.3M→-$12.6M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-18
ADDED
Words such as could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will, potential, opportunity, future and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Amid a broader industry renaissance in innate immunity highlighted by surging investment and clinical activity in NK, T, and iNKT-based therapies iNKT cells represent a distinct T cell ( T ) population that uniquely bridges innate and adaptive immunity.
They combine durable memory responses characteristic of adaptive T cells with rapid, MHC-independent rapid cytolytic capabilities of natural killer ("NK") cells.
This dual functionality enables direct tumor killing via CD1d and stress ligands, potent orchestration of the tumor microenvironment through activation of dendritic cells and NK cells, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function all while naturally suppressing graft-versus-host disease ("GvHD").
These indications include but are not limited critical pulmonary immune failure (including severe hypoxemic respiratory failure / pneumonia), GvHD, solid tumor cancers, and other severe immune-related diseases.
+7 more — sign up free →
REMOVED
Exhibits, Financial Statement Schedules 87 Item 16 Form 10-K Summary 89 i Note Regarding Forward Looking Statements This Annual Report on Form 10-K and other written and oral statements we make from time to time contain forward-looking statements.
You can identify these forward-looking statements by the fact they use words such as could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will, potential, opportunity, future and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.
Certain forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts.
These statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions.
iNKT cells represent a distinct T cell population, combining durable memory responses with the rapid cytolytic capabilities of natural killer ("NK") cells.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →